Nanoscope Therapeutics Prepares BLA Submission for MCO-010 in Retinitis Pigmentosa Following FDA Meeting
Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company dedicated to developing gene therapies for retinal degenerative diseases, has announced a successful FDA meeting for its clinic ...
Nanoscope Therapeutics’ MCO-010 Receives Fast Track Designation from FDA for Stargardt Disease Treatment
Nanoscope Therapeutics, a clinical-stage biotech company specializing in gene therapies for retinal disorders, announced that the US FDA has granted Fast Track Designation to MCO-010. an ambient-light ...